To better understand the outsourcing practices used by respondents’ companies, ISR asked research participants to provide an estimate for each of the activities shown below. Respondents from small and emerging biopharma companies rely heavily on CMOs for manufacturing activities. On average, 65 percent or more of the manufacturing activities listed below are outsourced. Small molecule API is outsourced at the highest rate, with 83 percent outsourced on average, and roughly two-thirds of respondents indicated 81 to 100 percent of small molecule API manufacturing is outsourced.
Learn more about how small & emerging sponsors contract for small molecule API manufacturing in our report Small Molecule API CDMO Benchmarking for Small & New Pharma.
Originally published in Life Science Leader.
View Resource